The receptor complex that mediates the biological activities of IL-6 consists of two distinct membrane-bound glycoproteins, an 80-kD cognate receptor subunit (IL-6R, CD126) and a 130-kD signal transducing element (gp130) ([@B1]). Although IL-6R expression is confined to select cell types, IL-6 can activate cells lacking the cognate receptor via a soluble IL-6 receptor (sIL-6R) ([@B2]). Once bound to IL-6, the resulting sIL-6R/IL-6 complex acts as an agonist that is capable of activating cells through membrane-bound gp130. Since expression of gp130 is essentially ubiquitous, the sIL-6R/IL-6 complex has the potential to stimulate cell types that are not inherently responsive to IL-6 alone. Recent studies show that the sIL-6R/IL-6 complex can induce myocardial hypertrophy ([@B3]), cellular proliferation ([@B4], [@B5]), and osteoclast formation ([@B6]). In addition, the active complex has been reported to regulate leukocyte recruitment ([@B7]), and to promote the proinflammatory stimulation of endothelial cells ([@B7], [@B8]). These latter findings appear to contrast with the antiinflammatory properties assigned by some to IL-6 ([@B9], [@B10]), and suggest that the sIL-6R/IL-6 complex not only potentiates IL-6 signaling, but may also modify its biological activities.

Two distinct isoforms of sIL-6R have been identified. The first is shed from the cell surface via proteolytic cleavage of the membrane-bound IL-6R (PC--sIL-6R \[11, 12\]), whereas the second is secreted as the product of differential mRNA splicing (DS--sIL-6R \[13, 14\]). The sIL-6R is present in the plasma of healthy individuals (∼25--35 ng/ ml), and these levels are significantly elevated in diseases such as rheumatoid arthritis, multiple myeloma, and T cell abnormalities such as AIDS and adult T cell leukemia (15-- 17). The increased concentration of sIL-6R in these disease states suggests that some inflammatory event either stimulates release of PC--sIL-6R, or increases the expression of DS--sIL-6R. Since the inflammatory potential of IL-6 is modulated through binding the sIL-6R, identifying physiological mediators of sIL-6R generation is of central importance to understanding the significance of this soluble receptor in disease.

Bacterial pore-forming toxins ([@B18]) and FMLP ([@B8]) are known to activate generation of PC--sIL-6R, whereas oncostatin-M was recently shown to stimulate the release of DS--sIL-6R from a human hepatoma cell line ([@B19]). However, to date no endogenously produced activator of PC-- sIL-6R shedding has been identified. In the present study, C-reactive protein (CRP), at concentrations likely to be encountered during an acute phase response, was found to provoke release of the membrane-bound IL-6R from human neutrophils. Thus, CRP has the potential to influence the inflammatory properties of IL-6 through facilitating formation of the sIL-6R/IL-6 complex.

Materials and Methods {#MaterialsMethods}
=====================

Materials.
----------

Culture reagents were obtained from GIBCO BRL, and purified human CRP from Calbiochem-Novabiochem Corp. Peptides corresponding to CRP amino acid residues 77--82 (VGGSEI), 174--185 (IYLGGPFSPNVL), and 201--206 (KPQLWP) were from Sigma Chemical Co. Biotinylated anti-- human IL-6R antibody (BAF-227) was from R&D Systems. Anti-DS--sIL-6R mAb (2F3) was generated as described previously ([@B20]). Dr. R.A. Black (Immunex Corp.) provided the TNF-α--protease inhibitor, TAPI. Lymphoprep was from Nycomed Pharma, and ImmunoPure 3,3′, 5,5′-tetramethylbenzidine (TMB) from Pierce Chemical Co.

Isolation of Human Neutrophils.
-------------------------------

Venous blood (20 ml) was obtained by antecubital venipuncture from nonsmoking healthy individuals (aged 26--54), mixed with an equal volume of 2% (wt/ vol) dextran/0.8% (wt/vol) trisodium citrate in PBS (pH 7.4), and erythrocytes were allowed to sediment. Plasma was collected, underlayered with Lymphoprep (2:1 \[vol/vol\] plasma/Lymphoprep), and centrifuged at 4°C for 20 min at 800 *g*. The neutrophil-containing pellet was collected, and contaminating erythrocytes were removed by hypotonic lysis. Neutrophil preparations were found to be \>95% pure as assessed by differential Wright staining. Before use, neutrophils were resuspended in serum-free RPMI 1640 containing 2 mM [l]{.smallcaps}-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin.

Determination of sIL-6R Production.
-----------------------------------

Neutrophils (2 × 10^6^ cells) were treated as described in the figure legends. Culture medium was harvested and stored at −80°C until required. Concentration of sIL-6R was determined using an ELISA procedure. Microtiter 96-well plates were coated with 10 μg/ml anti-- human IL-6R mAb (mAb 17.1; reference [@B21]) and blocked at 4°C with 0.5% BSA. sIL-6R standards and unknowns were added and incubated at room temperature for 2 h. To detect bound sIL-6R, biotinylated anti--human IL-6R antibody (50 ng/ml BAF-227) was added for 2 h at room temperature, followed by a 20-min incubation with horseradish peroxidase--conjugated streptavidin. Plates were washed between each step with PBS containing 0.1% Tween 20. Peroxidase activity was determined using TMB as a substrate. The reaction was stopped with 1.8 M H~2~SO~4~, and absorbance was measured at 450 nm. To detect DS--sIL-6R, the capture antibody was replaced with 20 μg/ml anti-DS--sIL-6R antibody (mAb 2F3), and ELISA was performed as described using baculovirus-expressed DS--sIL-6R as a standard ([@B20]). The lower limit of detection for sIL-6R and DS--sIL-6R was 10 and 50 pg/ml, respectively.

Flow Cytometry.
---------------

Loss of IL-6R expression from the neutrophil cell surface after stimulation was monitored by cytofluorometry (FACScan^®^; Becton Dickinson) as described ([@B20]). Values are expressed as the percent reduction in mean fluorescence units (MFU) from nonstimulated control cells: MFU = (FU~experimental~− FU~autofluorescence~)/(FU~control~ − FU~autofluorescence~).

Statistical Analysis.
---------------------

Statistical analysis was performed using Student\'s *t* test incorporated into the SigmaPlot (version 2.01) graphics program. A *P* \< 0.05 indicated a statistically significant difference.

Results {#Results}
=======

C-reactive Protein Stimulates Production of sIL-6R by Human Neutrophils.
------------------------------------------------------------------------

Examination of human neutrophils obtained from 10 independent donors showed that CRP activates sIL-6R production (Fig. [1](#F1){ref-type="fig"}). In each case, basal sIL-6R release was significantly increased (*P* \< 0.0001) after exposure to 50 μg/ml CRP, with the extent of sIL-6R production ranging between 86 and 234 pg/ml after CRP stimulation compared with 21--84 pg/ml for controls. On average, CRP resulted in a 3.06 ± 1.03--fold induction of sIL-6R levels (Fig. [1](#F1){ref-type="fig"} B). In contrast, activation of human neutrophils with IL-4 or IL-10 had no effect on sIL-6R generation (data not shown). As shown in Fig. [2](#F2){ref-type="fig"} A, production of sIL-6R increased rapidly, with optimal release occurring between 30 and 60 min after CRP addition. Generation of sIL-6R was also dose-dependent, with 50 μg/ml CRP inducing a maximal response (Fig. [2](#F2){ref-type="fig"} B). Release of the sIL-6R in response to a single exposure to CRP was transient, since levels returned to baseline within 4--5 h after stimulation. Addition of a second CRP dose 2 h after the initial CRP stimulation did not further enhance production (data not shown).

Peptides Derived from CRP Activate sIL-6R Production.
-----------------------------------------------------

Neutrophil stimulation has been shown to activate the cleavage of native CRP into biologically active peptide fragments ([@B22]). In particular, peptides corresponding to amino acid residues 77--82, 174--185, and 201--206 profoundly influence neutrophil responses ([@B23], [@B24]). Accordingly, human neutrophils were incubated with each of these peptides and their capacity to augment sIL-6R production was determined. As shown in Fig. [3](#F3){ref-type="fig"}, (174--185)CRP and (201--206)CRP stimulated sIL-6R production in a dose-dependent manner, whereas peptide (77--82)CRP had little or no effect.

CRP-activated Release of sIL-6R Occurs via Loss of the Cognate IL-6R.
---------------------------------------------------------------------

The sIL-6R can be released through proteolytic shedding of the cognate IL-6R or secreted as the product of differential IL-6R mRNA splicing ([@B11]--[@B14]). Flow cytometry using neutrophils from three separate donors showed that a 30-min exposure to 100 μg/ml native CRP resulted in a 44 ± 2.5% loss of the cognate IL-6R. Similarly, 100 μg/ml (174--185)CRP and (201--206)CRP stimulated a 33 ± 6.2% and 24 ± 0.3% reduction in the surface expression of IL-6R, respectively, whereas peptide (77--82)CRP had little effect (data not shown). This indicates a role for CRP in the activation of IL-6R shedding. To verify this conclusion, the concentration of DS--sIL-6R was determined in conditioned media from CRP-activated neutrophils, using an antibody specific for the unique COOH-terminal amino acid sequence (GSRRRGSCGL) of DS--sIL-6R ([@B20]). As shown in Table [I](#TI){ref-type="table"}, no detectable level of DS--sIL-6R could be identified either before or after CRP stimulation. Interestingly, no correlation could be established between elevated systemic CRP concentrations and DS--sIL-6R levels in patients suffering from various clinical disorders (Horiuchi, S., and N. Yamamoto, unpublished data).

Partial Inhibition of sIL-6R Production by TAPI.
------------------------------------------------

Hydroxamic acid--based metalloprotease inhibitors such as TAPI are known to prevent shedding of various cell surface proteins ([@B25]--[@B27]), including the IL-6R ([@B12], [@B20]). Surprisingly, the CRP-induced release of sIL-6R by neutrophils was only partially blocked by TAPI (∼20--25%; Fig. [4](#F4){ref-type="fig"}). Consistent with previous reports ([@B12], [@B20]), TAPI inhibited 70-- 75% of the phorbol ester--stimulated sIL-6R production by monocytic THP-1 cells (data not shown). Thus, the mechanism responsible for CRP-induced release of the cognate IL-6R from human neutrophils may be distinct from that described for monocytic cells.

Discussion {#Discussion}
==========

Elevated levels of the sIL-6R have been associated with the pathology of several disease states. This implies that production of the sIL-6R is increased as part of the inflammatory response. However, little is known regarding the factors that might regulate sIL-6R generation. In this study, physiological concentrations of native CRP and biologically relevant CRP-derived peptides were found to stimulate sIL-6R production by human neutrophils. Release of this soluble receptor was rapidly induced after CRP treatment and occurred via shedding of the cognate IL-6R from the cell surface. C-reactive protein represents the first known endogenous activator of this process. The observation that release of sIL-6R is only partially prevented by the hydroxamic acid--based metalloprotease inhibitor TAPI is of particular interest, since IL-6R shedding in response to phorbol esters and ionomycin has been shown to be prevented by this agent ([@B12], [@B20]). Thus, in neutrophils, shedding of the IL-6R presumably occurs through a unique proteolytic mechanism. Indeed, under certain experimental conditions the phorbol ester--induced shedding of L-selectin (CD62L) from human neutrophils has also been found to be only partially susceptible to a TAPI homologue ([@B27]).

In general, plasma CRP levels correlate with severity of inflammatory diseases. During the onset of inflammation or tissue injury, plasma concentrations of CRP are dramatically elevated from ∼1 μg/ml in healthy individuals to as much as 500 μg/ml during the acute phase response ([@B28]). In vitro studies have shown that control of this response is primarily regulated by IL-6 ([@B29]). More recently, human CRP-transgenic mice were used to verify in vivo that IL-6 is absolutely required for the induced expression of CRP during an inflammatory acute phase response ([@B30]). Our current findings show that this relationship between IL-6 and CRP is more complex than previously thought, since IL-6R shedding in response to CRP likely contributes to formation of the agonistic sIL-6R/IL-6 complex. Thus, CRP acts not only as an acute phase reactant, but it may have a profound effect on distal IL-6--mediated events that occur during the inflammatory process. Indeed, CRP levels in several diseases have been found to correlate with those of sIL-6R ([@B31]--[@B33]).

It is now recognized that CRP plays a significant role in host defense against pathogens ([@B34]). C-reactive protein also binds to specific receptors on human neutrophils and diminishes neutrophil responses, such as chemotaxis ([@B35]) and the activation of superoxide generation and degranulation by chemoattractants ([@B36]). In addition, CRP prevents neutrophil adhesion to endothelial cells via induction of L-selectin (CD62L) shedding ([@B37]). Consistent with these findings, in vivo studies have shown that CRP abates neutrophil recruitment in models of inflammation ([@B38], [@B39]). Taken together, these data indicate that CRP also performs an antiinflammatory function. It is therefore noteworthy that the sIL-6R/IL-6 complex has been shown to regulate proinflammatory activation of endothelial cells and to promote neutrophil recruitment ([@B7], [@B8]). In agreement with these findings, it has been observed that the extent of neutrophil infiltration into arthritic joints correlates with elevated sIL-6R levels in synovial fluid ([@B40]). It is conceivable that CRP may perform a pivotal role during inflammation by modulating the rate of neutrophil recruitment. It is also highly likely that CRP represents only one endogenous activator of IL-6R shedding, whereas release of DS--sIL-6R may also contribute to the overall properties of sIL-6R ([@B13], [@B14], [@B18]).

Previous studies have shown that peptides spanning residues 77--82 and 201--206 of the native CRP molecule block neutrophil superoxide generation and chemotaxis ([@B23], [@B24]), whereas peptide fragment 177--182 enhances cytokine/chemokine production and the tumoricidal activity of monocytic cells ([@B41]). Structure/function investigations of native CRP (for a review, see reference [@B34]) reveal that amino acids 77--82 reside within the phosphocholine (PCh)-binding site of the CRP molecule, whereas residues 174--185 and 201--206 form parts of the walls of a deep cleft on the opposite face of the CRP protomer. The shallow end of this cleft represents the C1q-binding site of CRP ([@B34]), whereas residues 175--179 are important for Fcγ-R1 binding ([@B42]). Interestingly, in the present study, CRP peptides 174--185 and 201--206 effectively augmented sIL-6R production by human neutrophils. However, release was not observed in response to residues 77-- 82. Similarly, CRP peptides 174--185 and 201--206, but not 77--82, were found to mediate L-selectin shedding ([@B37]). These data argue that the ability of CRP to stimulate IL-6R and L-selectin shedding from neutrophils involves interaction via the C1q/Fcg-R1 binding motif of CRP, and does not involve the PCh-binding site. Support for this concept is derived from the fact that disruption of the Ca^2+^-dependent interaction of PCh with CRP ([@B34]) through the addition of EDTA had no effect on the CRP-induced release of sIL-6R (data not shown).

Although neutrophils express relatively high levels of the cognate IL-6R, IL-6 signaling in these cells is poorly defined and appears to evoke only weak biological activities ([@B43], [@B44]). However, shedding of the IL-6R from human neutrophils has been shown to activate endothelial cells ([@B8]). As a result, expression of the IL-6R on neutrophils may primarily serve as an inducible source of sIL-6R. Thus, the activated shedding of the IL-6R from neutrophils may indirectly propagate the inflammatory response via stimulation of resident tissue cells by the sIL-6R/IL-6 complex.
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![Production of sIL-6R by CRP-activated human neutrophils. (A) Human neutrophils (2 × 10^6^ cells) from 10 independent donors were stimulated at 37°C, 5% CO~2~ with 50 μg/ml CRP for 30 min, and the concentration of sIL-6R in culture medium was determined by ELISA. Horizontal bars represent the mean sIL-6R concentration for control (43 pg/ml) and CRP-activated (129 pg/ml) neutrophils. The CRP-induced release of sIL-6R was statistically significant (*P* \< 0.0001) as determined by Student\'s *t* test. (B) The magnitude of CRP-induced sIL-6R production is shown for each donor. For controls, the mean concentration of 43 pg/ml was set to 1 and compared with the nonstimulated release for each donor. Values are expressed as mean fold induction ± SD (*n* = 10).](JEM981854.f1){#F1}

![Dose- and time- dependent release of the sIL-6R in response to CRP. Neutrophils (2 × 10^6^ cells) were stimulated at 37°C, 5% CO~2~with either (A) the indicated concentration of CRP for 45 min, or (B) for the indicated time period with (+CRP) and without (−CRP) 50 μg/ml CRP. After appropriate incubation, culture medium was harvested and sIL-6R concentrations were determined. Values represent the mean production ± SD (*n* = 3).](JEM981854.f2){#F2}

![Peptides derived from CRP activate sIL-6R production by human neutrophils. Neutrophils (2 × 10^6^ cells) were stimulated for 45 min at 37°C, 5% CO~2~with peptide (77--82)CRP, (174--185)CRP, or (201--206)CRP. sIL-6R concentrations are expressed as the mean ± SD (*n* = 3). Release of sIL-6R in response to 50 μg/ml CRP was 177.4 ± 6.5 pg/ml.](JEM981854.f3){#F3}

###### 

sIL-6R Derived from Differential mRNA Splicing Does Not Account for the CRP-induced Release of sIL-6R

  CRP          DS--sIL-6R      Total sIL-6R
  --------- -- ------------ -- ------------------------------------------------
  *μg/ml*      *pg/ml*         *pg/ml*
   0           \<LD              90.0 ± 10.6
   1           \<LD            96.8 ± 9.0[\*](#TFI-150){ref-type="table-fn"}
  10           \<LD            118.5 ± 13.4[‡](#TFI-152){ref-type="table-fn"}
  25           \<LD            178.0 ± 5.9[‡](#TFI-152){ref-type="table-fn"}
  50           \<LD            234.0 ± 17.4[‡](#TFI-152){ref-type="table-fn"}

Neutrophils (2 × 10^6^ cells) were stimulated with CRP for 45 min, and levels of total sIL-6R and DS--sIL-6R in conditioned medium were quantified (see Materials and Methods). Values represent the mean ± SD (*n* = 3). In the case of DS--sIL-6R, levels were below the limit of detection for the ELISA (\<LD).  

  *P* \< 0.05;  

  *P* \< 0.01 vs. nonstimulated control.  

![CRP-mediated sIL-6R production is partially inhibited by TAPI. Neutrophils (2 × 10^6^ cells) were pretreated for 10 min with either 100 μM TAPI (black bars) or vehicle alone (white bars) at 37°C, 5% CO~2~. Cells were stimulated for a further 40 min with 50 μg/ml CRP. Values are representative of three experiments and show mean sIL-6R production ± SD (*n* = 3).](JEM981854.f4){#F4}
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